Biologics in FDA’s 2025 Approvals: Implications for Future CMC Strategies
FDA’s 2025 approvals show biologics growing more complex. Learn why next-gen modalities demand stronger analytics, process design, and integrated CMC strategies.
Cutting edge process development insights and news from APC.
FDA’s 2025 approvals show biologics growing more complex. Learn why next-gen modalities demand stronger analytics, process design, and integrated CMC strategies.
In this presentation, Alexandra Bogdanovic, from APC’s bioprocess development team, delves into some of the key challenges and strategies associated with AAV production optimization.
This case study highlights the significance of particle size analysis via Dynamic Light Scattering (DLS) in the development of vaccines based on the MVA virus.
Automated assembly of hybrid dynamic models for CHO cell culture processes. Doyle, K., Tsopanoglou, A., Fejér, A., Glennon, B., & del Val, I. J. (2023)
APC & VLE founders Mark Barrett & Brian Glennon, receive Pharma Leader award for their innovative global centre of excellence in process dev & manufacturing.
[WEBINAR] Learn how mechanistic modelling + CFD to understand and optimize transfection and transduction efficiency can increase yield and lower costs.
A lack of process understanding & control leads to: inability to scale, product quality drift, & costly delays from batch failures & regulatory concerns
Tech transfer of Advanced Therapy Medicinal Products (ATMPs) presents additional challenges beyond those faced when transferring more traditional biologics.